entertainment -WSS

entertainment

author：leisure time 2025-09-30 08:45:57 - browse：47

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — The booming obesity market is attracting another player, as pharma giant Roche said Monday it was acquiring Carmot Therapeutics and the company’s line of weight loss drug candidates for $2.7 billion upfront.

The deal for Carmot, which is based in Berkeley, Calif., includes additional milestone payments of up to $400 million. Carmot is privately held, though it had filed paperwork last month for an initial public offering.

As part of the deal, Roche is gaining three experimental obesity medicines from Carmot, which are in Phase 1 or Phase 2 testing, as well as preclinical programs. While two are injectable treatments, one is being developed as an oral drug. They all target GLP-1 hormone receptors, while two are also designed to work via receptors for another hormone called GIP.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： JPM: CVS says Medicare Advantage patients are impacting profits

hotspot

WSS

Feng Zhang, Grail founder join forces on new gene editing startup

AdventHealth escalates lawsuit against insurance vendor Multiplan

Snackable artificial intelligence, expert AI, and the pharma industry

GSK Flovent asthma inhalers replaced by authorized generics

How a scoliosis diagnosis changed the life of one young dancer

Why Novartis is changing the name of its research labs

focus

entertainment

Wikipedia

Apple is now the first public company to be valued at $3 trillion

Chronically ill young patients struggle to find fertility info

Duchenne breakthrough therapy leaves behind pioneering families

AstraZeneca chief proposes a novel edit to the drug pricing bill

As demand for Covid shots wanes, Moderna seeks its next success

A new House health package & hospitals’ new site

Supreme Court strikes down use of affirmative action

Stem cell treatment guidelines are released by FDA

The high cost of giving birth even with insurance

Crinetics acromegaly drug succeeds in late

focus

JPM: CVS says Medicare Advantage patients are impacting profits

Amazon on where the company's health care bets are headed next

Medicaid rebukes states for mistakenly disenrolling children

How a scoliosis diagnosis changed the life of one young dancer

Why psychiatrists like me stop taking insurance

The FDA must approve intranasal treatments for anaphylaxis

hotspot

focus

leisure time

Wikipedia